Efficacy and safety of adalimumab in pediatric patients with Crohn’s disease: A systematic review and meta-analysis

• Published in: European journal of clinical pharmacology Vol. 80; no. 3; pp. 395 - 407
• Main Authors: Chen, Bin, Zou, Zhuan, Zhang, Xiaoyan, Xiao, Dongqiong, Li, Xihong
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2024; Springer Nature B.V
• Subjects: Adalimumab - adverse effects; Adalimumab - therapeutic use; Adolescent; Adverse events; Biomedical and Life Sciences; Biomedicine; Child; Children; Clinical trials; Crohn Disease - drug therapy; Crohn's disease; Humans; Meta-analysis; Monoclonal antibodies; Patients; Pediatrics; Pharmacology/Toxicology; Remission; Remission (Medicine); Remission Induction; Systematic review; Efficacy and safety; Adalimumab; Child; Crohn’s disease; Meta-analysis

Purpose There is currently no curative treatment for childhood Crohn’s disease (CD). This meta-analysis aimed to validate the efficacy and safety of adalimumab (ADA) in pediatric patients with CD. Materials and methods We searched all relevant studies in the PubMed, Web of Science, Embase, and Cochr...